# RELATIVITY-047

Source: https://onco.cc/trials/relativity-047/  
OnCo record `relativity-047` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Proved that adding a LAG-3 blocker to PD-1 blockade delays progression, with far less toxicity than the ipilimumab combination.

## Summary

PFS 10.1 vs 4.6 months (HR 0.75) led to FDA approval of Opdualag in March 2022. OS was not formally significant at first analysis; extended follow-up reported median OS 51.0 vs 34.1 months with 3-year OS 54.6% vs 48.0% (JCO 2024) and a 4-year update (EJC 2025) with the upper confidence bound below 1. Grade 3-4 treatment-related events ~21% versus ~59% for nivolumab-ipilimumab in CheckMate 067.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT03470922
- Phase: 2/3
- Setting: Untreated unresectable or metastatic melanoma: nivolumab + relatlimab (fixed dose) vs nivolumab
- Sponsor: BMS
- Enrolled: 714
- Result: PFS HR 0.75; median OS 51.0 vs 34.1 months.
- Outcomes: Progression-free survival: Nivolumab + relatlimab 10.1 months vs Nivolumab 4.6 months, HR 0.75; Overall survival (3-year): Nivolumab + relatlimab 54.6% vs Nivolumab 48%
- Replication: No independent phase 3 yet; the adjuvant RELATIVITY-098 trial of the same combination was negative, so the benefit appears specific to the advanced setting.

## Sources

- ClinicalTrials.gov NCT03470922: https://clinicaltrials.gov/study/NCT03470922
- 3-year OS, JCO 2024: https://ascopubs.org/doi/10.1200/JCO.24.01124
- 4-year update, EJC 2025: https://www.ejcancer.com/article/S0959-8049(25)00329-6/fulltext

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [LAG-3](https://onco.cc/targets/lag3/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/)
- trials: [CheckMate 067](https://onco.cc/trials/checkmate-067/), [Fianlimab + cemiplimab phase 3 (first-line melanoma)](https://onco.cc/trials/fianlimab-phase3-melanoma/)
- people: [Hussein A. Tawbi](https://onco.cc/people/hussein-tawbi/)
- key papers: [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/), [Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma](https://onco.cc/key-papers/paper-relativity-047-nejm-evid-2023-update/), [RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma](https://onco.cc/key-papers/paper-relativity-047-nejm-2022/)
- pairings: [Caution: LAG-3 blockade outside active disease](https://onco.cc/pairings/lag3-adjuvant-caution/)

---
JSON: https://onco.cc/api/v1/entities/relativity-047.json